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Sex Med 2Introduction: Previous studies have shown that the injection of adipose tissueederived stem cells (ADSCs) into
the tunica albuginea (TA) during the active phase of Peyronie’s disease (PD) prevents the development of ﬁbrosis.
Aim: To investigate, using an animal model, whether local injection of human ADSCs (hADSCs) can alter the
degree of ﬁbrosis in the chronic phase of PD.
Methods: 27 male, 12-week-old rats were divided into 3 equal groups: sham, PD without treatment, and PD
treated with hADSCs 1 month after disease induction. Sham rats underwent 2 injections of vehicle into the TA 1
month apart. PD rats underwent transforming growth factor b1 (TGFb1) injection and injection of vehicle 1
month later. PD-hADSC rats underwent TGFb1 injection followed by 1 million hADSCs 1 month later. 1 week
after treatment, n ¼ 3 animals/group were euthanized, and the penises were harvested for quantitative
polymerase chain reaction. 1 month after treatment, the other animals, n ¼ 6 per group, underwent
measurement of intracavernous pressure (ICP) and mean arterial pressure (MAP) during electrostimulation of the
cavernous nerve. After euthanasia, penises were again harvested for histology and Western blot.
Main Outcome Measure: The primary outcome measures included (a) gene expression at one week post-in-
jection; (b) measurement of ICP/MAP upon cavernous nerve stimulation as a measure of erectile function; (c)
elastin, collagen I and III protein expression; and (d) Histomorphometric analysis of the penis. Means where
compared by analysis of variance (ANOVA) followed by a Student-Newman-Keuls test for post hoc comparisons
or Mann-Whitney test when applicable.
Results: No signiﬁcant difference was noted in ICP or ICP/MAP in response to cavernous nerve electro-
stimulation between the 3 groups at 2.5, 5, and 7.5 V (P > .05 for all voltages). PD animals developed tunical
and subtunical areas of ﬁbrosis with a signiﬁcant upregulation of collagen III protein. The collagen III/I ratio was
higher in the PD (4.6 ± 0.92) group compared with sham (0.66 ± 0.18) and PD-hADSC (0.86 ± 0.06)
groups (P < .05) These ﬁbrotic changes were prevented when treated with hADSCs. Compared with PD rats,
PD-hADSC rats demonstrated a decreased expression of several ﬁbrosis-related genes.
Conclusion: Injection of hADSCs reduces collagen III expression in a rat model of chronic PD. Castiglione F,
Hedlund P, Weyne E, et al. Intratunical Injection of Human Adipose TissueeDerived Stem Cells Restores
Collagen III/I Ratio in a Rat Model of Chronic Peyronie’s Disease. Sex Med 2018;XX:XXeXX.
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Peyronie’s disease (PD) is a sexually debilitating ﬁbrotic
disease of the penis that results in penile deformity, impaired
penetrative intercourse, and signiﬁcant psychological stress for
patients and their partners.1 The prevalence of PD is estimated at
3.2% in the general male population, with rising incidence with
age and up to 9% in men with erectile dysfunction (ED).2 The
disease is characterized by the formation of a ﬁbrous plaque
within the tunica albuginea (TA) containing disarranged
depositions of collagen and elastin, which form during a painful
phase of inﬂammation (the acute phase).3 Ongoing inﬂamma-
tion during the acute phase results in aberrant wound healing
with the formation of a Peyronie’s plaque, leading to a
progressive penile curvature over a 12- to 18-month period.4
After this period, the scar tissue retracts, calciﬁes, and occa-
sionally ossiﬁes, resulting in a permanent and painless deformity
(the chronic phase).4 The penile deformity may present as a
curvature, waist deformity, or complex deformity with a
combination of waisting, rotation, and curvature, which result in
impaired penetrative intercourse. It is frequently accompanied by
severe and difﬁcult-to-treat ED.5 Currently there are no
evidence-based treatment options to halt the disease in the acute
phase.6 Therefore, patients have to undergo corrective penile
surgery, which is associated with penile shortening and devel-
opment of ED. The alternative option for less severe deformities
is injection of collagenase.5
The multipotent stromal cell (MSC) is characterized by its
ability to divide into a copy of itself and more terminally
differentiated daughter cells within the mesodermal lineage
(multipotency). However, this ability is not the only feature that
makes these cells appealing for therapeutic use. The secretion of a
broad range of paracrine factors, such as growth factors, cyto-
kines, and chemokines, makes MSCs able to inﬂuence and
modify their biological environment, speciﬁcally following tissue
injury.7 In this regard, MSCs have been attributed immuno-
modulatory, antiﬁbrotic, trophic, and free radicalescavenging
capabilities.8 Researchers have therefore used MSCs in various
ﬁbrotic conditions, in both the animal and the human setting,
and it is increasingly being recognized that MSCs may represent
a promising avenue of research in the prevention and treatment
of ﬁbrosis.9,10 The exact mechanisms of the antiﬁbrotic effects of
stem cell therapy still remain to be understood.11 One theory is
that stem cells act as a “drugstore,” inﬂuencing simultaneously
various ﬁbrogenic pathways.12 However, deﬁnitive answers have
not been given, and further research focusing on the mechanisms
of action are still ongoing.
Recently, several studies have suggested a possible role of
MSCs in the treatment of corpus cavernosum ﬁbrosis13,14 and
spongioﬁbrosis.15,16 In a previous study,17 our group showed the
efﬁcacy of human adipose tissueederived MSCs (ADSCs) in
preventing ﬁbrosis in a rat model of acute-phase PD. The rat is
most commonly used for the study of PD. This species exhibits
morphological and biological penile characteristics similar tothose of humans, has low costs for purchase and maintenance,
and offers excellent possibilities for experimental turnover and
multimethodological investigative approaches. Bivalacqua et al18
reported that injection of the recombinant transforming growth
factor b1 (TGFb1) protein produced similar effects but that a
combined intervention of surgical trauma and TGFb1 injection
caused more profound PD-like changes. Furthermore, either
procedure, alone or in combination, induced erectile
dysfunction.18
Clinically, the majority of patients present either late in the
acute phase or in the chronic phase, when the ﬁbrosis is estab-
lished.19 The aim of this study was to investigate the effects of a
local injection of ADSCs after establishment of TA ﬁbrosis in rat
model for chronic PD based on TGFb1 injection in TA.METHODS
Ethical Approval
All experiments on animals and human tissues were approved
by the ethics committee of the University Hospitals (registration
number: ML7263), Leuven, Belgium, and the Institutional
Ethical Committee for Animal Experimentation, KU, Leuven,
Belgium (Internal Review Board number P 272/2014). Informed
consent for adipose tissue processing was obtained
(B322201110944). We calculated a sample size of 18 consid-
ering 3 groups (6 animals for each group), a statistical power of
0.9, effect size d: 2, alpha level 0.05 (G*Power 3.1, University of
Düsseldorf, Germany). We included 9 other rats (3 for each
group) for gene expression investigation.Animals
Male Sprague Dawley rats (n ¼ 27; 12 weeks old; 300e350 g;
Charles River Laboratories, Wilmington, MA) were used. Rats
were housed in pairs under 12-hour reversed cycle lighting with
ad libitum access to food and water. Intraperitoneal ketamine
(75 mg/kg) and xylazine (50 mg/kg) were used for anesthesia for
the surgical procedures.20 Amoxicillin (50 mg/kg intraperitone-
ally) was administered 1 hour before the surgical procedures as
prophylaxis. Rats were euthanized using carbon dioxide asphyxia.Adipose TissueeDerived Stem Cell Isolation
Subcutaneous human adipose tissue was harvested from a
consenting female adult patient undergoing surgery for a benign
condition; the tissue was deemed surplus. ADSCs were isolated
as previously described.17 Brieﬂy, adipose tissue was minced and
rinsed with phosphate-buffered saline (PBS) and incubated in a
solution containing 0.075% collagenase type IA (Sigma-Aldrich,
St. Louis, MO) for 1 hour at 37C. This was shaken for 15e20
seconds every 20 minutes. The superﬁcial lipid layer was
removed, and the solution was centrifuged for 10 minutes at
1,000  g. The pellet was treated with 160 mM NH4Cl for 10
minutes to lyse red blood cells. The remaining cells were
suspended in 10 mL Dulbecco’s modiﬁed Eagle mediumSex Med 2018;-:e1ee10
Stem Cell Treatment for Peyronie’s Disease e3supplemented with streptomycin, fungizone, penicillin, and 10%
fetal bovine serum. The suspension was ﬁltered through a 70-mm
cell strainer, plated at a density of 1  106 cells in a 10-cm dish,
and cultured at 37C in 5% CO2. After 24 hours, the cells were
rinsed with PBS. Cells were cultured until passage 5, when they
were used for treatment. The cells were characterized using ﬂow
cytometry and tested for multiple lineage differentiation17 as
required by the International Society for Cellular Therapy.21Study Design
Rats were randomly divided into 3 equal groups. The sham
group (n ¼ 9) underwent injection of 50-mL vehicle (citrate
buffer) in the dorsomedial aspect of the right midshaft TA with a
microliter syringe after opening the buck fascia as previously
described.17 The remaining 18 animals were injected with 0.5 mg
recombinant TGFb1 in 50 mL vehicle.17 After 1 month, rats
received a second identical TA injection with either PBS (sham
and PD group) or 1 million ADSCs in PBS (PD-ADSC group).
1 week after the second treatment, 3 animals per group were
euthanized, and the penises were directly harvested during
anesthesia and snap frozen for gene expression investigation.22 4
weeks after the second treatment, 6 rats per group underwent
in vivo erectile function evaluation, after which the animals were
euthanized, and the penises were harvested for histological
analysis and protein extraction.Erectile Function Measurement
Intracavernous pressure (ICP) response to electrostimulation
of the cavernous nerve (CN) was used to evaluate erectile
function.17 Brieﬂy, under anesthesia, the right CN was exposed,
and the right crus of the corpus cavernosum was identiﬁed and
cannulated with a heparinized (200 U/ml) 25-G needle con-
nected to a pressure transducer. The CN was activated (2.5, 5,
and 7.5 V) by platinum electrodes connected to a stimulator at
20 Hz for 60 seconds.17 The nerve was stimulated once per
voltage, and a resting period of 2 minutes was allowed for nerve
recovery between stimulations. Mean arterial pressure (MAP)
was recorded by carotid artery cannulation.17Histological Analysis of Tissue
The penile midshaft at the level of the injection site was
harvested, ﬁxed, and further processed for histology. Hematox-
ylin and eosin and Masson’s trichrome staining procedures were
performed according to a standard protocol previously
described.20,22,23Western Blot Analysis
Western blot was performed as previously described20,22,23 for
the detection of collagen I, collagen III, and elastin proteins at
the level of the penile midshaft. Glyceraldehyde-3-phosphate
dehydrogenase (GADPH) was used as an internal standard.
Primary antibodies were rabbit antiecollagen III (1:1,000;
Abcam Inc, Cambridge, MA), mouse anti-elastin (1:500,Sex Med 2018;-:e1ee10Abcam), rabbit controls against GADPH (1:1,000, Santa Cruz
Biotechnology, Santa Cruz, CA), and rabbit antiecollagen I
(1:500; Abcam).20,22,23Gene Expression Evaluation Using Fibrosis-Focused
Quantitative Polymerase Chain Reaction Array
The expression of 84 genes associated with ﬁbrosis was eval-
uated using reverse transcription-2 polymerase chain reaction
(PCR) array system (PAMM-120; SA Biosciences, Antwerp,
Belgium).22,24 The urethra and dorsal neurovascular compart-
ment were stripped from the corpora cavernosa, and the
remaining corporal tissue and TA were homogenized in Trizol
reagent followed by puriﬁcation with the RNEasy system
(Qiagen, Valencia, CA). RNA was reverse-transcribed and
ampliﬁed using PCR with the reagents recommended by the
manufacturer. Normalized gene expression data were derived by
the 2eDDCT method. Gene expression values were normalized to
the reference genes b-actin, hypoxanthine phosphoribosyl-
transferase1, b-2-microglobulin, and GADPH.22,24 The expres-
sion of each gene in the PD and PD-ADSC groups was reported
as fold increase of the mean expression of the same gene in the
sham group. Differences in gene expression22,24 were considered
signiﬁcant with P < .05 using analysis of variance (ANOVA).Statistical Analysis
The results were analyzed using Prism v.4 (GraphPad Software,
San Diego, CA) and expressed as mean and standard deviation of
the mean. Multiple groups were compared using 1-way ANOVA
followed by the StudenteNewmaneKeuls test for post hoc
comparisons. Statistical signiﬁcance was set at P < .05.22,24
RESULTS
Erectile Function
No signiﬁcant difference was noted in the ICP and ICP/MAP
in response to cavernous nerve electrostimulation between the 3
groups (n ¼ 6 per group) at 2.5, 5, and 7.5 volts (P > .05 for all
voltage) 4 weeks after vehicle or hADSC injection (Figure 1,
Supplemental Figure 1).Histological and Western Blot Analysis
Rats injected with TGFb1 (PD group) displayed a deposition
of amorphic matrix and a haphazard organization of collagen
ﬁbers in the TA which extended into the subtunical corpus
cavernosum (Figure 2). These morphologic results were corrob-
orated by quantitative Western blot analysis, which revealed an
increased protein content of collagen III and elastin compared to
the sham group (P < .05 for both) (Figure 3 and Supplemental
Figure 2). In the PD-hADSC group, the overall structure of the
TA and collagen III expression of the penile shafts were com-
parable to those of sham rats (Figure 3). Penile shafts from PD-
hADSC rats showed more elastin expression than the sham
group (P < .02) and had slightly increased expression of collagen
AB
Figure 1. Erectile function measurement. Summarized data
comparing erectile function measurements in sham PD rats and
rats treated with adipose tissueederived stem cells at various
voltages during cavernous nerve electrostimulation in analysis of
variance with post hoc StudenteNewmaneKeuls analysis. A, ICP.
B, ICP normalized over mean arterial pressure. hADSC ¼ human
adipose tissueederived stem cell; ICP ¼ intracavernous pressure;
PD ¼ Peyronie’s disease.
e4 Castiglione et alI compared with the PD and sham groups (P < .05) (Figure 3).
Interestingly, the collagen III/I ratio was higher in the PD (4.6 ±
0.92) group compared with sham (0.66 ± 0.18) and PD-hADSC
groups (0.86 ± 0.06; P ¼ .01; n ¼ 6 per group).Gene Expression
In an exploratory experiment (n ¼ 3 per group), 32 genes
were differentially expressed in PD and PD-hADSC groups
compared with the sham group (P < .05) (Figure 4). 6 genes
were differentially expressed in PD and PD-hADSC groups: C-C
motif chemokine ligand 13 (CCL13); C-X-C motif chemokine
receptor 4 (CXCR4); plasminogen activator, tissue type (PLAT);
serpin family H member 1 (serpinh1); TGFb1; and tumor ne-
crosis factor (TNF) (P < .05).DISCUSSION
We provide novel evidence that xenotransplantation of
hADSCs reduces TA ﬁbrosis in a rat model representing the
chronic phase of PD. PD is a ﬁbrotic disorder of the penis char-
acterized by the development of a plaque in the tunica albuginea.4
Fibrosis itself can be considered a result of abnormal woundhealing.25 Wound healing is an intricate pathophysiological pro-
cess, involving a coordinated production of growth factors, cyto-
kines, and extracellular matrix (ECM) and crosstalk betweenmany
cell types. The fact that diverse diseases in different organ systems
are associated with ﬁbrotic changes implies common intricate
pathogenic pathways.26 The aforementioned intricate pathway
likely suggests the complexity of ﬁbrosis development, and it partly
explains why an efﬁcacious antiﬁbrotic treatment has yet to be
established.27 As stated by El Agha et al,28 “it might be that a single
anti-ﬁbrotic magic bullet is simply unable to override such
multifactorial and complex diseases.”
Fibrotic disease embodies a varied spectrum of disorders and is
characterized by a disproportionate accumulation of ECM ele-
ments, comprising interstitial collagens (types I and III), cellular
ﬁbronectin, and basal membrane proteins such as laminin.26
Collagens are primarily structural proteins composed of 3
procollagen chains conﬁgured in a classic triple helical pattern.
Early in the course of wound healing, myoﬁbroblasts deposit
type III collagen.29 Type III collagen belongs to the ﬁbrillary
collagen group and is the predominating tensile ECM until the
later phase of wound healing, when it is replaced by the stronger
type I collagen.30 Most ﬂexible tissues (skin, intestine, blood
vessels, lung, TA) have a III/I ratio of 1 to 2e3.31 Fibrotic tissues
are associated with a shift in the normal III/I ratio toward an
increase in the content of collagen III.31
The rapidly expanding and highly promising body of pre-
clinical work in stem cell medicine provides a potential cure for
ﬁbrotic diseases such as lung, kidney, and heart ﬁbrosis.32e34 All
the available antiﬁbrotic drugs act against 1 step of the redundant
and intricate ﬁbrotic pathway. Conversely, stem cells are able to
counteract ﬁbrosis acting in multiple steps and not as a single
weapon.35 This characteristic makes stem cells potentially supe-
rior to the currently available treatments.
In our previous study,17 we showed that in the acute or
inﬂammatory phase of the disease, injection of hADSCs into the
affected area prevents formation of ﬁbrosis and elastosis in the
tunica and corpus cavernosum and restores erectile function.
In this study, we injected the hADSCs 1 day after the TGFb1
treatment, aiming to mimic the early phase of the disease,
which is characterized by inﬂammation, penile pain, curvature
progression, and no stable identiﬁable ﬁbrotic plaque.17 After 1
month, rats injected with TGFb1 (PD group) displayed exten-
sive TA and corporal ﬁbrosis and elastosis at the injection site
together with impaired erectile function.17 Although this study
provided a proof of principle for the efﬁcacy of stem cells in
treating PD, most patients present to their healthcare provider
with later stages of PD, and thus these results cannot be directly
translated into clinical application.19
In the present study, we injected the hADSCs 1 month after
TGFb1 injection, trying to replicate a condition similar to the
chronic phase of PD. During the chronic phase, since the in-
ﬂammatory process has settled, pain is absent and the penile
curvature is stable. Interestingly, in our study, 2 months afterSex Med 2018;-:e1ee10
Figure 2. Histology. Representative photomicrographs of Masson’s trichrome and H&E staining in midshaft sections of rat penises at
magniﬁcation 10, 20, and 40. A and B, H&E staining on sections from a sham rat (A) and corresponding Masson’s trichrome staining
on an adjacent section from the same rat (B). C and D, H&E on sections from a PD rat (C) and corresponding Masson’s trichrome staining
on an adjacent section from the same rat (D). E and F, H&E sections from a hADSC-treated PD rat (E) and corresponding Masson’s
trichrome staining on an adjacent section from the same rat. (F) Note the open cavernous sinusoids in the sham rats (*) and the
surrounding normal bilayer structure of the tunica albuginea (#). In PD rats, there is deposition of amorphic extracellular matrix material ($).
In the PDþhADSC group, there is an increase in extracellular matrix deposition (þ); however, collagen ﬁbers seem better organized and
sinusoid structure is largely preserved. hADSC ¼ human adipose tissueederived stem cell; H&E ¼ hematoxylin and eosin; PD ¼ Peyronie’s
disease.
Stem Cell Treatment for Peyronie’s Disease e5TGFb1 injection, the PD rats showed less ﬁbrosis on histological
analysis than detected after 1 month in the previous study.17
Based on these data, it appears that the ﬁbrotic plaques in the
TA tend to partially regress spontaneously after 60 days in the
TGFb1 rat model of PD. This regression may be a limitation of
the TGFb1 PD model for the study of the condition in the long
term. Furthermore, in contrast to the previous study, we did not
detect any signiﬁcant corporal ﬁbrosis, and plaques were limited
to the tunica and the immediate subtunical area. This may
explain the lack of erectile function impairment in the PD group
compared with the sham rats, although it should be noted that
differences were signiﬁcant but small in the acute study.17 In the
present study, we showed that late ADSC therapy was able to
reduce the expression of collagen III but had no effect on
collagen I and elastin expression. Conversely, in our previous
study we showed that early hADSC treatment was able to pre-
vent elastosis; however, in both studies hADSC treatment was
able to restore the collagen III/I ratio.
Our results are in line with the 2 preclinical studies performed
by Gokce et al.36,37 Those studies had evaluated the efﬁcacy of
allogeneic ADSCs and genetically modiﬁed allogeneic ADSCs
expressing human interferon A-2b for the prevention and, more
importantly, the treatment of TA ﬁbrotic plaques. In the ﬁrst
study,37 the allogeneic ADSCetreated groups received tunicaSex Med 2018;-:e1ee10albuginea injections with 0.5 million rat ADSCs immediately
after (early phase) or 1 month after (late phase) the TGFb1
injection. 6 weeks after TGFb1 injection, in both prevention
and treatment groups, TA injection of ADSCs resulted in
signiﬁcantly lower tunica albuginea ﬁbrosis and a better erectile
function response compared with the rats treated only with
TGFb1. In the second study, Gokce et al36 compared the efﬁ-
cacy of ADSCs expressing human interferon A-2b and normal
allogeneic ADSC in the prevention and treatment of PD using a
similar design to the previous study. The results of that study
showed that both types of cells are effective in preventing and
treating Peyronie’s-like changes, but interestingly, ADSCs
expressing human interferon A-2b induced a better recovery of
erectile function.36
To further preliminarily identify potential mechanisms that
may be involved in the antiﬁbrotic effect by hADSCs, we pro-
ﬁled expressions of ﬁbrosis-associated genes in the 3 groups. We
found that 32 genes involved in different pathways and steps of
the wound healing process were differentially expressed by PD
and PD-hADSC groups compared with the sham group. 6 genes
were differentially expressed in PD and PD-hADSC groups:
CCL13, CXCR4, PLAT, serpinh1, TGFb1, and TNF. These
preliminary genomic data, despite requiring a conﬁrmation with
far more in-depth experiments using protein expression analysis,
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Figure 3. Western blot analysis for collagen III, collagen I, and elastin. A, Representative chemiluminescence images of blotted membranes
containing protein extracts of all 3 groups. Double bands are caused by binding of antibodies to glycosylated and nonglycosylated forms of
these molecules. B, Summarized protein expression levels for elastin; *P < .05 vs both PD and PD-hADSC in ANOVA with post hoc
StudenteNewmaneKeuls analysis. C, Summarized protein expression levels for collagen I; ***P < .05 vs both PD and sham in ANOVA with
post hoc StudenteNewmaneKeuls analysis. D, Summarized protein expression levels for collagen III; **P < .05 vs both sham and
PD-hADSC in ANOVA with post hoc StudenteNewmaneKeuls analysis. E, Collagen III and I expression ratio; **P < .05 vs both sham and
PD-hADSC in ANOVA with post hoc StudenteNewmaneKeuls analysis. ANOVA ¼ analysis of variance; GAPDH ¼ glyceraldehyde 3-phosphate
dehydrogenase; hADSC ¼ human adipose tissueederived stem cell; PD ¼ Peyronie’s disease.
e6 Castiglione et alare in line with the current idea that stem cells do not act on a
single target but by altering the local inﬂammatory environ-
ment.8,38,39 Indeed, a growing body of evidence suggests that
MSCs act via a plethora of effects including, but not limited to,
immunomodulation, reactive oxygen species neutralization, and
angiogenesis.8,38,39Even if the current approach to using xenogeneic stem cells
offers a novel option for the management of PD, it may be
regarded as a limitation compared with autologous grafting,
which may be a more attractive procedure from a therapeutic
perspective. However, MSCs, including ADSCs, have been
shown to be immunomodulatory and immunosuppressive, andSex Med 2018;-:e1ee10
Figure 4. Continued.
Sex Med 2018;-:e1ee10
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Figure 4. Fibrosis-associated gene expression (3 rats per group). The expression of each gene in the PD rat and PD-hADSC groups was
reported as a fold increase of the mean expression of the same gene of the sham group. Differences in gene expression were considered
signiﬁcant when P< .05 by analysis of variance. *P< .05 versus sham and PD. **P < .05 versus both Sham and PD-hADSC groups. ***P <
.05 versus Sham. ****P < .05 versus PD group. ACTA2 ¼ alpha-actin-2; CCL13 ¼ chemokine (C-C motif) ligand 13; CCR2 ¼ C-C chemokine
receptor type 2; COL1A ¼ collagen, type I, alpha 1; CTGF ¼ connective tissue growth factor; CXCR4 ¼ C-X-C chemokine receptor type 4;
DCN ¼ decorin; EDN1 ¼ endothelin 1; GREM1 ¼ gremlin 1; IL5 ¼ interleukin 5; ITGA1 ¼ integrin subunit alpha 1; ITGA2 ¼ integrin subunit
alpha 2; ITGAV ¼ integrin subunit alpha V; ITGB1 ¼ integrin subunit beta 1; ITGB5 ¼ integrin subunit beta 5; ITGB8 ¼ integrin subunit beta
8; ITBP1 ¼ integrin beta-1-binding protein 1; JUN ¼ un proto-oncogene; LOX ¼ lysyl oxidase; MMP1 ¼matrix metallopeptidase 1; MMP3 ¼
matrix metallopeptidase 3; PLAT ¼plasminogen activator, tissue type; SERPINH1 ¼ serpin family H member 1; SMAD4 ¼mothers against
decapentaplegic homolog 4; THBS1 ¼ thrombospondin-1; TGFB1 ¼ transforming growth factor beta-1 proprotein; TGFB2 ¼ transforming
growth factor beta-2 proprotein; TGFB3 ¼ transforming growth factor beta-3 proprotein; TIMP2 ¼metalloproteinase inhibitor 2; TIMP3 ¼
metalloproteinase inhibitor 2; TNF ¼ tumor necrosis factor; VEGEFA ¼ vascular endothelial growth factor.
e8 Castiglione et altheir xenogeneic transplantation in immunocompetent animals
was extensively evaluated. Indeed, ADSCs have been shown to
lack major histocompatibility complex II expression and its
immunosuppressive effects mediated by prostaglandin E2.40e42
Furthermore, the genetic expression results need to be
validated with protein expression analysis.
More importantly, in the TGFb1 rat chronic model of PD,
the absence of erectile dysfunction, together with the evidencethat the ﬁbrotic plaques of TA tend to partially regress
spontaneously after 60 days, represent important limits of the
study.CONCLUSION
Local injection of hADSCs in a rat model of chronic PD
signiﬁcantly decreased the collagen III/I ratio in the TA. FurtherSex Med 2018;-:e1ee10
Stem Cell Treatment for Peyronie’s Disease e9animal and clinical studies are needed to conﬁrm the promising
translational potential of this treatment strategy.
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